Patents by Inventor Gary V. Johnson

Gary V. Johnson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for the preparation of growth hormone and antagonist thereof having lower levels of isoform impurities thereof
    Patent number: 8148331
    Abstract: The present invention is directed generally to recombinant methods for making a desired polypeptide. These method(s) yield a polypeptide product containing reduced levels of isoform impurities thereof. In particular, the present invention is directed to (1) a recombinant method for preparing growth hormone with reduced isoform impurities thereof and (2) a recombinant method for preparing a growth hormone antagonist, such as pegvisomant, and its protein intermediate, also having reduced isoform impurities thereof. More specifically, the isoform impurities that are decreased by methods of the present invention are the trisulfide and des-phe isoform impurities of growth hormone and growth hormone antagonist (or its intermediate), respectively.
    Type: Grant
    Filed: March 17, 2009
    Date of Patent: April 3, 2012
    Assignee: Pfizer Inc.
    Inventors: Anurag S. Rathore, Stephen B. Lyle, David E. Steinmeyer, Scott I. Allen, John Meyer, Denis M. Boyle, John J. Buckley, Gary V. Johnson
  • Method for the Preparation of Growth Hormone and Antagonist Thereof Having Lower Levels of Isoform Impurities Thereof
    Publication number: 20100021966
    Abstract: The present invention is directed generally to recombinant methods for making a desired polypeptide. These method(s) yield a polypeptide product containing reduced levels of isoform impurities thereof. In particular, the present invention is directed to (1) a recombinant method for preparing growth hormone with reduced isoform impurities thereof and (2) a recombinant method for preparing a growth hormone antagonist, such as pegvisomant, and its protein intermediate, also having reduced isoform impurities thereof. More specifically, the isoform impurities that are decreased by methods of the present invention are the trisulfide and des-phe isoform impurities of growth hormone and growth hormone antagonist (or its intermediate), respectively.
    Type: Application
    Filed: March 17, 2009
    Publication date: January 28, 2010
    Inventors: Anurag Rathore, Stephen B. Lyle, David E. Steinmeyer, Scott I. Allen, John Meyer, Denis M. Boyle, John J. Buckley, Gary V. Johnson
  • Process for decreasing aggregate levels of pegylated protein
    Patent number: 7470779
    Abstract: The present invention is directed generally to recombinant methods for making a desired pegylated protein and pooling of same. The method(s) yield a polypeptide product containing reduced levels of aggregate thereof pooled to provide the desired pegylated isoforms thereof.
    Type: Grant
    Filed: September 22, 2003
    Date of Patent: December 30, 2008
    Assignee: Pfizer Inc.
    Inventors: Denis M. Boyle, John J. Buckley, Gary V. Johnson, David E. Steinmeyer, Michele Toal, Serdar Aykent, Anurag S. Rathore
  • Formulation, Solubilization, Purification, and Refolding of Tissue Factor Pathway Inhibitor
    Publication number: 20080281084
    Abstract: Compositions are described that are suitable for formulating TFPI. Solubilizers and stabilizers facilitate the preparation of pharmaceutically acceptable compositions of TFPI at various concentrations.
    Type: Application
    Filed: April 5, 2007
    Publication date: November 13, 2008
    Applicants: Novartis Vaccines and Diagnostics, Inc., G. D. Searle LLC
    Inventors: Glenn J. Dorin, Bo H. Arve, Gregory L. Pattison, Robert F. Halenbeck, Kirk Johnson, Bao-Lu Chen, Raisharan K. Rana, Maninder S. Hora, Hassan Madani, Michael Tsang, Mark E. Gustafson, Gary S. Bild, Gary V. Johnson
  • Formulation, solubilization, purification, and refolding of tissue factor pathway inhibitor
    Patent number: 7226757
    Abstract: Compositions are described that are suitable for formulating TFPI. Solubilizers and stabilizers facilitate the preparation of pharmaceutically acceptable compositions of TFPI at various concentrations.
    Type: Grant
    Filed: January 24, 2006
    Date of Patent: June 5, 2007
    Assignees: G.D. Searle LLC, Novartis Vaccines and Diagnostics, Inc.
    Inventors: Glenn J. Dorin, Bo H. Arve, Gregory L. Pattison, Robert F. Halenbeck, Kirk Johnson, Bao-Lu Chen, Raisharan K. Rana, Maninder S. Hora, Hassan Madani, Michael Tsang, Mark E. Gustafson, Gary S. Bild, Gary V. Johnson
  • Formulation, solubilization, purification, and refolding of tissue factor pathway inhibitor
    Patent number: 7022672
    Abstract: A method of modifying protein solubility employs polyionic polymers. These facilitate the solubilization, formulation, purification and refolding of proteins especially incorrectly folded proteins and aggregated proteins. Compositions are described that are suitable for formulating TFPI. The compositions allow preparation of pharmaceutically acceptable compositions of TFPI at concentrations above 0.2 mg/mL and above 10 mg/mL.
    Type: Grant
    Filed: November 30, 2001
    Date of Patent: April 4, 2006
    Assignees: Chiron Corporation, G. D. Searle, LLC
    Inventors: Glenn J. Dorin, Bo H. Arve, Gregory L. Pattison, Robert F. Halenbeck, Kirk Johnson, Bao-Lu Chen, Rejsharan K. Bana, Maninder S. Hoba, Hassan Madani, Michael Tsang, Mark E. Gustafson, Gary S. Bild, Gary V. Johnson
  • Method for the preparation of growth hormone and antagonist thereof having lower levels of isoform impurities thereof
    Publication number: 20040048315
    Abstract: The present invention is directed generally to recombinant methods for making a desired polypeptide. These method(s) yield a polypeptide product containing reduced levels of isoform impurities thereof. In particular, the present invention is directed to (1) a recombinant method for preparing growth hormone with reduced isoform impurities thereof and (2) a recombinant method for preparing a growth hormone antagonist, such as pegvisomant, and its protein intermediate, also having reduced isoform impurities thereof. More specifically, the isoform impurities that are decreased by methods of the present invention are the trisulfide and des-phe isoform impurities of growth hormone and growth hormone antagonist (or its intermediate), respectively.
    Type: Application
    Filed: August 25, 2003
    Publication date: March 11, 2004
    Applicant: Pharmacia Corporation
    Inventors: Anurag Rathore, Stephen B. Lyle, David E. Steinmeyer, Scott I. Allen, John Meyer, Denis M. Boyle, John J. Buckley, Gary V. Johnson
  • Formulation, solubilization, purification, and refolding of tissue factor pathway inhibitor
    Publication number: 20020137884
    Abstract: A method of modifying protein solubility employs polyionic polymers. These facilitate the solubilization, formulation, purification and refolding of proteins especially incorrectly folded proteins and aggregated proteins. Compositions are described that are suitable for formulating TFPI. The compositions allow preparation of pharmaceutically acceptable compositions of TFPI at concentrations above 0.2 mg/mL and above 10 mg/mL.
    Type: Application
    Filed: November 30, 2001
    Publication date: September 26, 2002
    Applicant: Chiron Corporation
    Inventors: Glenn J. Dorin, Bo H. Arve, Gregory L. Pattison, Robert F. Halenback, Kirk Johnson, Bao-Lu Chen, Rajsharan K. Bana, Maninder S. Hoba, Hassan Madani, Michael Tsang, Mark E. Gustafson, Gary S. Bild, Gary V. Johnson
  • Method of solubilizing, purifying, and refolding protein
    Patent number: 6323326
    Abstract: A method of modifying protein solubility employs polyionic polymers. These facilitate the solubilization, formulation, purification and refolding of proteins especially incorrectly folded proteins and aggregated proteins. Compositions are described that are suitable for formulating TFPI. The compositions allow preparation of pharmaceutically acceptable compositions of TFPI at concentrations above 0.2 mg/mL and above 10 mg/mL.
    Type: Grant
    Filed: June 11, 1999
    Date of Patent: November 27, 2001
    Assignees: Chiron Corporation, G. D. Searle & Co.
    Inventors: Glenn J. Dorin, Bo H. Arve, Gregory L. Pattison, Robert F Halenbeck, Kirk Johnson, Bao-Lu Chen, Rajsharan K. Rana, Maninder S. Hoba, Hassan Madani, Michael Tsang, Mark E. Gustafson, Gary S. Bild, Gary V. Johnson
  • Method of solubilizing, purifying, and refolding protein
    Patent number: 6319896
    Abstract: A method of modifying protein solubility employs polyionic polymers. These facilitate the solubilization, formulation, purification and refolding of proteins especially incorrectly folded proteins and aggregated proteins. Compositions are described that are suitable for formulating TFPI. The compositions allow preparation of pharmaceutically acceptable compositions of TFPI at concentrations above 0.2 mg/mL and above 10 mg/mL.
    Type: Grant
    Filed: November 18, 1999
    Date of Patent: November 20, 2001
    Assignees: Chiron Corporation, G.D. Searle & Co.
    Inventors: Glenn J. Dorin, Bo H. Arve, Gregory L. Pattison, Robert F. Halenbeck, Kirk Johnson, Bao-Lu Chen, Rajsharan K. Rana, Maninder S. Hora, Hassan Madani, Michael Tsang, Mark E. Gustafson, Gary S. Bild, Gary V. Johnson
  • Compositions for dissolution of soft metals
    Patent number: 5824631
    Abstract: A liquid composition useful for selective dissolution of soft metal is disclosed. The composition comprises an organic nitrocompound and a carboxylic acid. The organic nitrocompound, upon exposure to the soft metal, oxidizes the soft metal to form a first soft metal salt. The carboxylic acid, upon exposure to the soft metal salt, react with the first soft metal salt to form a second soft metal salt that is soluble in the composition. Related methods are also disclosed.
    Type: Grant
    Filed: May 29, 1997
    Date of Patent: October 20, 1998
    Inventors: John H. Wagenknecht, Gary V. Johnson
  • Method for dissolution of soft metals from a substrate of a harder metal
    Patent number: 5565039
    Abstract: A method for selectively dissolving a soft metal from a substrate of a harder metal by application thereto of an organic nitrocompound and a carboxylic acid. The organic nitrocompound, upon exposure to the soft metal, oxidizes the soft metal to form a first soft metal salt. The carboxylic acid, upon exposure to the soft metal salt, reacts with the first soft metal salt to form a second soft metal salt that is soluble in the composition.
    Type: Grant
    Filed: August 11, 1995
    Date of Patent: October 15, 1996
    Inventors: John H. Wagenknecht, Gary V. Johnson
  • Protective sports cap
    Patent number: D710058
    Type: Grant
    Filed: November 8, 2012
    Date of Patent: July 29, 2014
    Inventor: Gary V. Johnson